Johnson & Johnson Paying $1B For Oncology Startup Firefly
Johnson & Johnson said Monday it has agreed to acquire Firefly Bio Inc. for $1 billion in cash, adding a proprietary technology that targets hard-to-treat tumors. ...To view the full article, register now.
Already a subscriber? Click here to view full article